Structure Therapeutics Inc
GPCR17.480USD
-0.110-0.63%
交易中 （美东）报价延迟15分钟
3.02B总市值
亏损市盈率 TTM
关于 Structure Therapeutics Inc 公司
Structure Therapeutics Inc. 是一家临床阶段的全球生物制药公司，致力于开发用于代谢和心肺疾病的新型口服小分子疗法。该公司专注于 G 蛋白偶联受体 (GPCR) 作为治疗靶点类别。其候选产品包括 GSBR-1290、Amylin、葡萄糖依赖性胰岛素促泌多肽受体 (GIPR)、GCGR、ANPA-0073 和 LTSE-2578。该公司正在开发 GSBR-1290，这是其口服小分子候选产品，针对经过验证的胰高血糖素样肽-1 受体 (GLP-1R)，用于治疗 2 型糖尿病 (T2DM) 和肥胖症。该公司正在开发 GLP-1R 候选药物，包括双重 GLP-1R/GIPR 激动剂和 Amylin 激动剂，每种药物都具有定制特性，可实现额外益处。该公司正在开发 ANPA-0073，这是一种在研口服小分子 APJR 激动剂，用于治疗特发性肺纤维化 (IPF)。该公司正在评估其 LPA1R 项目 LTSE-2578，用于治疗 IPF 和进行性肺纤维化。
公司简介
公司代码GPCR
公司名称Structure Therapeutics Inc
上市日期Feb 03, 2023
CEODr. Raymond Stevens, Ph.D.
员工数量163
证券类型Depository Receipt
年结日Feb 03
公司地址611 Gateway Blvd Suite 223
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编94080
电话16282299277
网址https://structuretx.com/
公司代码GPCR
上市日期Feb 03, 2023
CEODr. Raymond Stevens, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Xichen Lin, Ph.D.
Dr. Xichen Lin, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
62.07K
+1142.70%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
41.17K
--
Ms. Yingli Ma
Ms. Yingli Ma
Chief Technology Officer
Chief Technology Officer
31.82K
+332.50%
Ms. Sharon Tetlow
Ms. Sharon Tetlow
Independent Director
Independent Director
--
--
Mr. Jun Yoon
Mr. Jun Yoon
Chief Financial Officer, Co-Founder
Chief Financial Officer, Co-Founder
--
--
Dr. Joanne Waldstreicher, M.D.
Dr. Joanne Waldstreicher, M.D.
Independent Director
Independent Director
--
--
Mr. Eric L. Dobmeier, J.D.
Mr. Eric L. Dobmeier, J.D.
Independent Director
Independent Director
--
--
Dr. Blai Coll, M.D., Ph.D.
Dr. Blai Coll, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Angus Russell
Mr. Angus Russell
Independent Director
Independent Director
--
--
Dr. Raymond Stevens, Ph.D.
Dr. Raymond Stevens, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Xichen Lin, Ph.D.
Dr. Xichen Lin, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
62.07K
+1142.70%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
41.17K
--
Ms. Yingli Ma
Ms. Yingli Ma
Chief Technology Officer
Chief Technology Officer
31.82K
+332.50%
Ms. Sharon Tetlow
Ms. Sharon Tetlow
Independent Director
Independent Director
--
--
Mr. Jun Yoon
Mr. Jun Yoon
Chief Financial Officer, Co-Founder
Chief Financial Officer, Co-Founder
--
--
Dr. Joanne Waldstreicher, M.D.
Dr. Joanne Waldstreicher, M.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月9日 周五
更新时间: 5月9日 周五
持股股东
股东类型
持股股东
持股股东
占比
Wellington Management Company, LLP
13.54%
Fidelity Management & Research Company LLC
10.08%
Janus Henderson Investors
7.57%
Deep Track Capital LP
7.13%
Capital Research Global Investors
3.76%
Other
57.93%
持股股东
持股股东
占比
Wellington Management Company, LLP
13.54%
Fidelity Management & Research Company LLC
10.08%
Janus Henderson Investors
7.57%
Deep Track Capital LP
7.13%
Capital Research Global Investors
3.76%
Other
57.93%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
38.24%
Investment Advisor
31.60%
Hedge Fund
22.90%
Venture Capital
4.66%
Individual Investor
3.08%
Research Firm
2.11%
Private Equity
1.86%
Pension Fund
0.06%
Bank and Trust
0.03%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
379
60.17M
104.57%
-15.84M
2025Q1
381
62.21M
108.14%
-12.86M
2024Q4
357
66.09M
115.26%
-5.81M
2024Q3
330
65.93M
115.14%
-2.45M
2024Q2
298
63.40M
110.86%
+11.42M
2024Q1
239
45.01M
96.54%
-1.29M
2023Q4
210
43.42M
93.57%
+9.41M
2023Q3
125
33.38M
93.24%
+15.44M
2023Q2
64
17.69M
49.41%
+2.82M
2023Q1
49
14.88M
38.91%
+11.89M
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Wellington Management Company, LLP
7.79M
13.54%
+5.57K
+0.07%
Mar 31, 2025
Fidelity Management & Research Company LLC
5.80M
10.08%
-218.60K
-3.63%
Mar 31, 2025
Janus Henderson Investors
4.36M
7.57%
+195.31K
+4.69%
Mar 31, 2025
Deep Track Capital LP
4.10M
7.13%
+1.10M
+36.67%
Mar 31, 2025
Capital Research Global Investors
2.16M
3.76%
-1.37M
-38.82%
Mar 31, 2025
Vestal Point Capital, LP
1.79M
3.11%
+63.99K
+3.71%
Mar 31, 2025
BVF Partners L.P.
1.77M
3.08%
--
--
Mar 31, 2025
Capital International Investors
1.62M
2.81%
-55.00
-0.00%
Mar 31, 2025
RA Capital Management, LP
1.52M
2.64%
--
--
Mar 31, 2025
Driehaus Capital Management, LLC
1.27M
2.21%
-784.67K
-38.14%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Roundhill GLP-1 & Weight Loss ETF
3.88%
TrueShares Technology, AI & Deep Learning ETF
2.57%
Amplify Weight Loss Drug & Treatment ETF
1.86%
WisdomTree BioRevolution Fund
1.24%
Tema Heart & Health ETF
1.01%
Virtus LifeSci Biotech Clinical Trials ETF
0.84%
ALPS Medical Breakthroughs ETF
0.81%
American Century Focused Dynamic Growth ETF
0.28%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
查看更多
Roundhill GLP-1 & Weight Loss ETF
占比3.88%
TrueShares Technology, AI & Deep Learning ETF
占比2.57%
Amplify Weight Loss Drug & Treatment ETF
占比1.86%
WisdomTree BioRevolution Fund
占比1.24%
Tema Heart & Health ETF
占比1.01%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.84%
ALPS Medical Breakthroughs ETF
占比0.81%
American Century Focused Dynamic Growth ETF
占比0.28%
ProShares Ultra Nasdaq Biotechnology
占比0.14%
Invesco Nasdaq Biotechnology ETF
占比0.14%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
